N~1~,N~2~-二甲基甘氨酸酰胺 | 44565-47-1

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 甘氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N~1~,N~2~-二甲基甘氨酸酰胺
• 中文别名: N-甲基-2-(甲基氨基)乙酰胺；N-甲基-2-甲基甘氨酰胺盐酸盐；N-甲基-2-甲基氨基-乙酰胺盐酸盐
• 英文名称: N¹,N²-dimethylglycinamide
• 英文别名: N-methyl-2-(methylamino)acetamide；N,N'-dimethylglycinamide；sarcosine N-methylamide；N-methylsarcosamide；N-methyl-glycine methylamide；sarcosine methylamide
• CAS: 44565-47-1
• 化学式: C₄H₁₀N₂O
• mdl: MFCD06375938
• 分子量: 102.136
• InChiKey: NODGJSNKUCVLNN-UHFFFAOYSA-N

物化性质

• 沸点：
  241.6±23.0 °C(Predicted)
• 密度：
  0.934±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  7
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2924199090
• 储存条件：
  存于2-8°C环境中，避免光照，保持干燥密封。

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : N1,N2-Dimethylglycinamide
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
The product does not need to be labelled in accordance with EC directives or respective national laws.
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 102,14 g/mol
No components need to be disclosed according to the applicable regulations.

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Avoid
breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
No data available
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  N~1~,N~2~-二甲基甘氨酸酰胺 在 劳森试剂 作用下， 以 苯 为溶剂， 反应 12.0h， 生成 N-methyl-2-(methylamino)ethanethioamide
  参考文献：
  名称：

  含硫酰胺的二肽和类肽-肽杂种的构象特征—计算和实验方法

  摘要：

  讨论了硫酰胺掺入N，N-二甲基-2-（N-甲基乙酰胺基）乙酰胺和N-甲基-2-（N-甲基乙酰胺基）乙酰胺作为二肽结构和类肽-肽杂化物的最简单模型的影响。通过自然键轨道（NBO）分析增强的计算以及使用NMR光谱通过动力学和平衡测量进行的实验，检查了模型化合物的溶剂调节构象特征。通过NBO分析所支持的计算表明主要的那内在稳定性的反式异构体（α d和C 7β的dipeptoid模型结果的形式）从间接Ñ→π*相互作用，发生在羰基氧孤对（n）和相邻的酰胺羰基的π*轨道通过C–H反键（σ*）之间。n →π*直接相互作用对反式稳定作用的贡献可忽略不计。N-末端硫代取代增加了这种间接电子离域，使得α d异构体普遍。所述Ñ X →σ N'C-H *相互作用是的稳定性的额外来源的反式-C 7β形成相关的未衍生dipeptoid模型和其C末端硫代酰胺对应物。在类肽-肽杂种中，反式巯基和羰基之间氢键供体-受体能力

  DOI：

  10.1021/acs.jpca.8b05456
• 作为产物：
  描述：

  2-氯-N-甲基乙酰胺 、 甲胺 以 四氢呋喃 为溶剂， 反应 24.0h， 生成 N~1~,N~2~-二甲基甘氨酸酰胺
  参考文献：
  名称：

  The structure-activity profile of mercaptobenzamides’ anti-HIV activity suggests that thermodynamics of metabolism is more important than binding affinity to the target

  摘要：

  Mercaptobenzamide thioesters and thioethers are chemically simple HIV-1 maturation inhibitors with a unique mechanism of action, low toxicity, and a high barrier to viral resistance. A structure-activity relationship (SAR) profile based on 39 mercaptobenzamide prodrug analogs exposed divergent activity/toxicity roles for the internal and terminal amides. To probe the relationship between antiviral activity and toxicity, we generated an improved computational model for the binding of mercaptobenzamide thioesters (SAMTs) to the HIV-1 NCp7 C-terminal zinc finger, revealing the presence of a second low-energy binding orientation, hitherto undisclosed. Finally, using NMR-derived thiol -thioester exchange equilibrium constants, we propose that thermodynamics plays a role in determining the antiviral activity observed in the SAR profile. (C) 2019 Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2019.06.020

文献信息

• [EN] SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME<br/>[FR] COMPOSÉS 1,1'-BIPHÉNYLE SUBSTITUÉS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ARBUTUS BIOPHARMA INC

  公开号：WO2021158481A1

  公开（公告）日：2021-08-12

  The present invention includes substituted 1,1'-biphenyl compounds, analogues thereof, and compositions comprising the same. In one aspect, the compounds contemplated in the invention can be used to treat, ameliorate, or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient. In another aspect, the compounds contemplated in the invention can be used to treat, ameliorate, and/or prevent cancer in a patient.

  本发明包括取代的1,1'-联苯化合物，其类似物，以及包含它们的组合物。在一个方面，本发明中考虑的化合物可用于治疗、改善或预防患者体内的乙型肝炎病毒（HBV）和/或丙型肝炎病毒（HDV）感染。在另一个方面，本发明中考虑的化合物可用于治疗、改善和/或预防患者体内的癌症。
• A Modular Construction of Epidithiodiketopiperazines
  作者：Thomas N. Snaddon、Toya D. Scaggs、Colin M. Pearson、James W. B. Fyfe

  DOI：10.1021/acs.orglett.9b01770

  日期：2019.6.21

  activities and have attracted significant synthetic attention. The preparation of analogues is actively pursued; however, they are structurally challenging, and more direct and modular methods for their synthesis are desirable. To this end, the utility of a bifunctional triketopiperazine building block for the straightforward synthesis of ETPs is reported. A modular strategy consisting of enolate alkylation

  表二硫代二酮哌嗪类（ETP）具有非常多样的生物学活性，并引起了合成方面的极大关注。积极进行类似物的制备；然而，它们在结构上具有挑战性，并且需要更直接和模块化的方法来合成它们。为此，报道了双功能三酮哌嗪结构单元用于ETP的直接合成的效用。由烯醇化烷基化然后进行位点选择性亲核试剂加成组成的模块化策略使得能够精确合成（±）-透明质酸和一系列类似物。
• Synthesis of piperazine-2,5-diones related to bicyclomycin: 3-acetoxy-1,4-dibenzyl-3-[1-(2-methoxyethyl)- and 1-(2-hydroxyethyl)ethenyl]piperazine-2,5-dione. 1. Route via acyclic intermediates
  作者：Peter Yates、John Harold Hoare

  DOI：10.1139/v83-091

  日期：1983.3.1

  3-Acetoxy-1,4-dibenzyl-3-[1-(2-methoxyethyl)ethenyl]piperazine-2,5-dione (32) and its 2-hydroxyethyl analogue (46), which possess several of the structural features of the antibiotic bicyclomycin, have been synthesized by a route involving construction of the piperazine-2,5-dione ring at a late stage in the reaction sequence. Treatment of ethyl 3-(2-methoxyethyl)-3-methylglycidate with acetic anhydride and sulfuric acid gives ethyl 2-acetoxy-3-(2-methoxyethyl)-3-butenoate (10), which is converted to the corresponding carboxylic acid by ethanolysis, hydrolysis, and reacetylation. This, on conversion to its acid chloride and reaction with N,N′-dibenzylglycinamide, gives 2-acetoxy-N-benzyl-N-(2-benzylamino-2-oxocthyl)-3-(2methoxyethyl)-3-butenamide (21). Compound 21, on hydrolysis and oxidation, gives the corresponding 2-oxo compound, which on treatment with magnesium isopropylcyclohexylamide followed by acetylation yields 32. Demethylation of 21 with alkylthiotrimethylsilanes gives the corresponding 2-hydroxyethyl compound, whose tetrahydropyranyl ether on subjection to the above reaction sequence gives the 2-(tetrahydropyran-2-yloxy)ethyl analogue of 32. This, on hydrolysis, gives a 3: 1 mixture of compound 46 and a spiro compound formed by displacement of the acetoxyl group by the hydroxyl oxygen atom of 46.

  3-乙酰氧基-1,4-二苄基-3-[1-(2-甲氧基乙基)乙烯基]哌嗪-2,5-二酮(32)及其2-羟乙基类似物(46)，具有抗生素双环霉素的几个结构特征，通过在反应序列后期构建哌嗪-2,5-二酮环的路线合成。将乙基3-(2-甲氧基乙基)-3-甲基缩水甘油酸酯与乙酸酐和硫酸处理得到乙基2-乙酰氧基-3-(2-甲氧基乙基)-3-丁烯酸酯(10)，通过乙醇解、水解和再乙酰化转化为相应的羧酸。将其转化为酸酐并与N,N′-二苄基甘氨酰胺反应，得到2-乙酰氧基-N-苄基-N-(2-苄胺基-2-氧辛基)-3-(2-甲氧基乙基)-3-丁烯酰胺(21)。化合物21经水解和氧化得到相应的2-氧代化合物，再与异丙基环己基胺镁处理后进行乙酰化，得到32。用烷基硫三甲基硅烷对21进行脱甲基化得到相应的2-羟乙基化合物，其四氢吡喃基醚经上述反应序列得到32的2-(四氢吡喃-2-基氧基)乙基类似物。经水解后得到化合物46与由46的乙酰氧基被羟基氧原子取代形成的螺环化合物3:1混合物。
• Darstellung von Trijod-isophthalsäure-monoaminosäureamiden und ihre Verwendung als Röntgenkontrastmittel
  作者：E. Klieger、E. Schröder

  DOI：10.1002/ardp.19733061106

  日期：——

  Aminosäureamiden 2 zu den entsprechenden Nitro‐isophthalsäure‐Derivaten 3, die nach Verseifung, katalytischer Druckhydrierung, Jodierung und schließlich Acylierung die Titelverbindungen 7 liefern Die Präparate eignen sich vorzüglich als Röntgenkontrastmittel für die Uro‐, Angio‐ und Myelographie.

  以硝基间苯二甲酸单甲酯氯化物 (1) 为原料，与氨基酸酰胺 2 反应生成相应的硝基间苯二甲酸衍生物 3，经皂化、催化加压加氢、碘化，最后酰化得到标题化合物 7。非常适合用作尿路、血管和脊髓造影的 X 射线造影剂。
• Assignment of the Liposidomycin Diazepanone Stereochemistry
  作者：Spencer Knapp、Gregori J. Morriello、Santosh R. Nandan、Thomas J. Emge、George A. Doss、Ralph T. Mosley、Lijian Chen

  DOI：10.1021/jo010355g

  日期：2001.8.1

  and C-3'". An intramolecular reductive amination reaction has been used to prepare model diazepanones. Analysis of 40 and two of its diastereomers by NMR spectroscopy, X-ray crystallography, and molecular modeling indicates a close relative configurational and conformational match between 40 and the liposidomycin diazepanone degradation product 43 and allows the assignment of stereochemistry of the

  脂质霉素包括抑制细菌肽聚糖合成的复杂核苷类抗生素。它们的结构（1、2）具有核苷，呋喃核糖苷，二氮杂酮和脂质区域。几个立体定位中心尚未分配，包括在地西pan酮区域内的三个：C-6'，C-2'“和C-3'”。分子内还原胺化反应已用于制备模型二氮杂酮。通过NMR光谱，X射线晶体学和分子建模对40个及其两个非对映异构体进行分析，结果表明40与脂环霉素二氮杂酮降解产物43之间的构象和构象匹配非常接近，并且可以将天然产物的立体化学指定为[ C-6'（R），C-2'“（R），C-3'”（R）]或[C-6'（S），C-2'“（S），